Hodgkin and non-Hodgkin lymphoma in children: successes and challenges

Published:August 31, 2021DOI:https://doi.org/10.1016/j.paed.2021.08.002


      Paediatric lymphomas constitute a little over 10% of all cancers in children and fall into one of two pathological classes: Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL). The clinical presentation and management differ for HL and NHL and their associated subgroups. For most childhood lymphoma, current treatment strategies result in high cure rates. However this comes with the significant burden of the late effects of treatment in some patient groups, particularly with the use of radiotherapy in HL. The treatment of relapsed and refractory disease poses significant challenges for the increasingly small populations for whom there are specific unmet clinical needs. A wider understanding of the molecular basis of both disease response and resistance is required to inform an individualized approach to treatment. In this review, we will give a clinical overview of classical HL and NHL with an emphasis on presentation and management.


      To read this article in full you will need to make a payment

      Key references

        • Landman-Parker J.
        • Wallace H.
        • Hasenclever D.
        • et al.
        First International inter-group study for classical Hodgkin lymphoma in children and adolescents: EuroNet-PHL-C1.
        Haematologica. 2016; 101 (Report of the latest interim analyses): P064
        • Rosolen A.
        • Perkins S.L.
        • Pinkerton C.R.
        • et al.
        Revised international pediatric non-hodgkin lymphoma staging system.
        J Clin Oncol. 2015; 33: 2112-2118
        • Patte C.
        • Auperin A.
        • Gerrard M.
        • et al.
        Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
        Blood. 2007; 109: 2773-2780
        • Minard-Colin V.
        • Auperin A.
        • Pillon M.
        • et al.
        Rituximab for high-risk, mature B-cell non-hodgkin's lymphoma in children.
        N Engl J Med. 2020; 382: 2207-2219

      Further reading

        • Cairo M.S.
        • Coiffier B.
        • Reiter A.
        • Younes A.
        • Panel T.L.S.E.
        Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
        Br J Haematol. 2010; 149: 578-586
        • Cairo M.S.
        • Gerrard M.
        • Sposto R.
        • et al.
        Results of a randomized international study of high risk central nervous system B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukemia in children and adolescents.
        Blood. 2007; 109: 2736-2743
        • Gerrard M.
        • Cairo M.S.
        • Weston C.
        • et al.
        Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
        Br J Haematol. 2008; 141: 840-847
        • Prokoph N.
        • Larose H.
        • Lim M.S.
        • Burke G.A.A.
        • Turner S.D.
        Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond.
        Cancers (Basel). 2018; 10: 99